GlassScriptPhysician profile
Pratap Saraf
NPI 1356317242
$9,552.31
in general payments reported to CMS, 2019-2025
42 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $693 · 2021: $1,821 · 2022: $1,745 · 2023: $1,444 · 2024: $1,579 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,617 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,616.70 |
| Education | $218.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,788.45 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,658.51 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Harmony Biosciences LLC | $1,347.65 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $433.37 | 2019-2023 | Yupelri |
| Insmed, INC. | $416.20 | 2021-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $379.91 | 2020-2025 | Tezspire, Breztri, Airsupra |
| Grifols USA, LLC | $333.31 | 2019-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $288.60 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $280.39 | 2020-2024 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $266.61 | 2022 | |
| Axsome Therapeutics, INC. | $216.96 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $189.55 | 2021-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $182.24 | 2022-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Sanofi-Aventis U.S. LLC | $173.94 | 2023-2025 | |
| Genzyme Corporation | $162.45 | 2021-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $147.19 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $139.43 | 2019-2024 | Uptravi, Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $97.91 | 2024-2025 | Lumryz |
| Electromed, INC. | $95.55 | 2021-2025 | Smartvest |
| Advanced Respiratory, INC | $87.36 | 2021 | |
| Mallinckrodt Hospital Products INC. | $78.35 | 2020-2024 | Acthar |
| Pfizer INC. | $77.54 | 2022-2024 | |
| Viatris Specialty LLC | $74.03 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $67.45 | 2022-2023 | Quviviq |
| Baxter Healthcare | $58.26 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $53.11 | 2023-2024 | Avycaz |
| Inspire Medical Systems, INC. | $47.75 | 2024-2025 | Inspire |
| Lilly USA, LLC | $46.61 | 2025 | Zepbound |
| Optinose US, INC. | $41.71 | 2024-2025 | |
| Genentech USA, INC. | $41.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.26 | 2021 | |
| Philips North America LLC | $34.56 | 2021-2025 | Sleep Service |
| Verona Pharma, INC. | $26.34 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $25.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.97 | 2023 | Hetlioz |
| Ani Pharmaceuticals, INC. | $24.28 | 2024 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $22.68 | 2019 | |
| Allergan, INC. | $19.80 | 2019 | |
| Phadia US INC. | $17.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.01 | 2021 | |
| Vifor Pharma, INC. | $16.92 | 2024 | Zemaira |
| Janssen Pharmaceuticals, INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratap Saraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.